Walmart has always prioritized “everyday low prices” for their customers. Now, the superstore is extending that pledge to their own brand of affordable insulin for those with diabetes.
The company announced in a press release today, “Available exclusively through Walmart’s private ReliOn brand, the new offering includes analog insulin vials ($72.88) and FlexPen ($85.88).” Based on calculations of patients purchasing the products without insurance, Walmart claims they will save customers between 58 and 75 percent off the typical price of analog insulin.
“We know many people with diabetes struggle to manage the financial burden of this condition, and we are focused on helping by providing affordable solutions,” Dr. Cheryl Pegus, executive vice president of Walmart Health & Wellness, explained. “We also know this is a condition that disproportionately impacts underserved populations. With ReliOn NovoLog insulin, we’re adding a high-quality medication for diabetes to the already affordable ReliOn line of products and continuing our commitment to improve access and lowering cost of care.”
This launch comes after years of drastically increasing prices for insulin from leading pharmaceutical manufacturers. Tracey D. Brown, chief executive officer of the American Diabetes Association, shared in the press release that diabetes treatment costs an average of $9,601 for just one patient each year. “We welcome all affordable solutions that make diabetes management more accessible to millions of Americans living with diabetes,” she added. “We encourage everyone to ask their health care provider questions to better understand what the right and affordable treatment is for their unique medical needs.”
The ReliOn insulin will be available at Walmart stores this week and in their Sam’s Club stores starting mid-July. Customers will, of course, need a prescription from their doctor. You can find more information about the insulin products and other resources provided by the company at Walmart.com/diabetes.
We certainly hope this news helps more people get the treatment they need without worrying about it draining their bank account.
We write about products we think our readers will like. If you buy them, we get a small share of the revenue from the supplier.